for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sangamo Therapeutics Inc

SGMO.O

Latest Trade

7.47USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

6.95

 - 

13.91

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.47
Open
--
Volume
--
3M AVG Volume
34.44
Today's High
--
Today's Low
--
52 Week High
13.91
52 Week Low
6.95
Shares Out (MIL)
115.94
Market Cap (MIL)
877.65
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q4 2019 Sangamo Therapeutics Inc Earnings Release

Latest Developments

More

Sangamo Announces Early Completion Of Transfer To Pfizer Of SB-525 Hemophilia A Gene Therapy IND

Sangamo Says First 3 Patients In Study Evaluating ST-400 Ex Vivo Gene-Edited Cell Therapy In Beta Thalassemia Experienced Prompt Hematopoietic Reconstitution

Sangamo Therapeutics Reports Q3 Loss Per Share Of $0.24

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.

Contact Info

501 Canal Blvd

+1.510.9706000

https://www.sangamo.com/

Executive Leadership

Alexander D. Macrae

President, Chief Executive Officer, Director

Sung Lee

Chief Financial Officer, Executive Vice President

Stephane Boissel

Interim Chief Financial Officer

Prathyusha Durabaibu

Principal Accounting Officer

Adrian Woolfson

Executive Vice President of Research and Development

Key Stats

2.25 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-1.020

2017

-0.700

2018

-0.700

2019(E)

-1.228
Price To Earnings (TTM)
--
Price To Sales (TTM)
11.79
Price To Book (MRQ)
2.09
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-21.82
Return on Equity (TTM)
-19.11

Latest News

Latest News

BRIEF-Sangamo Therapeutics Increased Size Of Board To Nine Members From Eight

* SANGAMO THERAPEUTICS INC - ON FEB 11, BOARD OF DIRECTORS INCREASED SIZE OF BOARD TO NINE MEMBERS FROM EIGHT Source: (https://bit.ly/3266fYZ) Further company coverage:

BRIEF-Sangamo Therapeutics Appoints John Markels To Board Of Directors

* SANGAMO THERAPEUTICS APPOINTS JOHN MARKELS TO ITS BOARD OF DIRECTORS

Sangamo Therapeutics shares dive after poor early-stage trial data

Sangamo Therapeutics Inc's shares sank 27 percent on Thursday after its gene-editing drug failed to show promise in an early-stage trial testing it in patients with ultra-rare disorders.

BioMarin sets stage early for hemophilia cure off-Broadway

(This version of the November 21st story has been refiled to show in paragraph 23 that Sangamo Therapeutics has six people in clinical trials)

BRIEF-Bioverativ And Sangamo Announce FDA Acceptance Of Ind Application For Gene-Edited Cell Therapy BIVV003

* BIOVERATIV AND SANGAMO ANNOUNCE FDA ACCEPTANCE OF IND APPLICATION FOR GENE-EDITED CELL THERAPY BIVV003 TO TREAT SICKLE CELL DISEASE

BRIEF-Sangamo Therapeutics Reports Q1 Loss Per Share Of $0.23

* SANGAMO THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Sangamo Therapeutics Prices Public Offering Of Common Stock

* SANGAMO THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Sangamo Therapeutics Proposes Public Offering Of Common Stock

* SANGAMO THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Sangamo Therapeutics Files For Potential Mixed Shelf Offering

* SANGAMO THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING Source text (https://bit.ly/2vH7vVF) Further company coverage:

BRIEF-Sangamo Therapeutics Says Co Announced A Data Security Incident Involving Compromise Of A Senior Executive's Company Email Account

* SANGAMO THERAPEUTICS SAYS ON APRIL 17, CO ANNOUNCED A DATA SECURITY INCIDENT INVOLVING COMPROMISE OF A SENIOR EXECUTIVE'S COMPANY EMAIL ACCOUNT

Sangamo in $3 billion gene-editing deal with Gilead

U.S. drugmaker Gilead Sciences Inc <GILD.O> will use Sangamo Therapeutics Inc's <SGMO.O> gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion (2.16 billion pounds) to Sangamo, the companies said on Thursday.

Gilead signs $3 bln licensing deal for Sangamo's gene-editing platform

Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology platform to develop cancer treatments, in a collaboration deal worth more than $3 billion, the two companies said on Thursday.

BRIEF-Sangamo Therapeutics Q4 Loss Per Share $0.15

* SANGAMO THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Kite And Sangamo Therapeutics Announce Collaboration To Develop Cell Therapies For Treatment Of Cancer

* KITE, A GILEAD COMPANY, AND SANGAMO THERAPEUTICS ANNOUNCE COLLABORATION TO DEVELOP NEXT-GENERATION ENGINEERED CELL THERAPIES FOR THE TREATMENT OF CANCER

BRIEF-Sangamo Therapeutics Appoints Heather Turner As Senior Vice President

* SANGAMO THERAPEUTICS ANNOUNCES APPOINTMENT OF HEATHER D. TURNER AS SENIOR VICE PRESIDENT AND GENERAL COUNSEL Source text for Eikon: Further company coverage:

BRIEF-Case Western Reserve, Sangamo Therapeutics get $11 Mln NIH Grant

* CASE WESTERN RESERVE AND SANGAMO THERAPEUTICS ANNOUNCE $11 MILLION NIH GRANT FOR STUDY OF GENE-EDITED T CELLS FOR VIRAL ERADICATION OF HIV

Sangamo partners with Pfizer to develop gene therapy for ALS

Sangamo Therapeutics Inc and Pfizer Inc said on Wednesday they would work together to develop a gene therapy to treat ALS, a disease that affects nerve cells in the brain and the spinal cord.

BRIEF-Sangamo And Pfizer Announce Collaboration For Development Of Zinc Finger Protein Gene Therapy For Als

* SANGAMO AND PFIZER ANNOUNCE COLLABORATION FOR DEVELOPMENT OF ZINC FINGER PROTEIN GENE THERAPY FOR ALS

BRIEF-Sangamo Therapeutics posts Q3 loss per share $0.15

* Sangamo Therapeutics reports third quarter 2017 financial results

BRIEF-Sangamo and Bioverativ announce FDA acceptance of IND application for ST-400

* Sangamo and Bioverativ announce FDA acceptance of IND application for ST-400 -- a gene-edited cell therapy candidate -- to treat beta-thalassemia

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up